Logo

AstraZeneca's Trixeo Aerosphere Receives EU's Approval for the Maintenance Treatment of COPD

Share this

AstraZeneca's Trixeo Aerosphere Receives EU's Approval for the Maintenance Treatment of COPD

Shots:

  • The approval is based on P-lll ETHOS involve the assessing of Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) vs Bevespi Aerosphere and PT009 in adult patients with mod. to sev. COPD. P-III KRONOS study also supported the approval
  • The study showed a reduction in rate of mod. or sev. exacerbations. EMA’s CHMP has recommended the MAA for Trixeo Aerosphere in Oct’2020
  • Trixeo Aerosphere is a single-inhaler- fixed-dose triple-combination of formoterol fumarate LABA- LAMA- with budesonide- an ICS- and delivered in a pressurized metered-dose inhaler. The approval marks the fourth major approval of the therapy

 ­ Ref: AstraZeneca | Image: The Scientist Magazine

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions